ATHLONE, Ireland, May 24, 2016 (GLOBE NEWSWIRE) -- Innocoll (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company, today announced that the Company will host a live webcast and conference call to review top-line results of its two, identical Phase 3 studies of XARACOLL® (bupivacaine-collagen bioresorbable implant) for the treatment of postoperative pain relief immediately following open abdominal hernia repair.
The webcast and call will take place on Wednesday, May 25, 2016 at 8:30 AM Eastern Daylight Time. A press release announcing the top-line results will be issued prior to the webcast. Interested parties may access the webcast through the Investors section of our website or directly through the registration link.
About Innocoll
Innocoll is a global, commercial-stage, specialty pharmaceutical company that is dedicated to engineering better medicines. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to wound and/or surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL for the treatment of postoperative pain; INL-002, a gentamicin-collagen topical matrix for the adjuvant treatment of diabetic foot infections; and INL-003, a collagen barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, Pioneer, Biomet 3i and Biomet. All of our native collagen products—from extraction/purification of type-1 collagen through final delivery form—are manufactured at our certified, integrated plant in Saal, Germany.
For more information, please visit www.innocoll.com.